The Antibody Drug Conjugate (ADC) contract manufacturing market is at the forefront of the precision medicine revolution. Known as "biological missiles," ADCs combine the targeting specificity of monoclonal antibodies with the cell-killing potency of cytotoxic payloads. Because the production of these therapies requires a complex fusion of biologic manufacturing and high-potency...